SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The health sector is navigating various challenges, including debates over drug pricing in the EU, pest agreements between ...

LIMA, Peru (AP) — LIMA, Peru (AP) — Cementos Pacasmayo SAA (CPAC) on Monday reported profit of $14.2 million in its first quarter. The Lima, Peru-based company said it had profit of 16 cents per share ...

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...